Dialysis XXXX with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study.

@entity1 @entity712 @entity64 @entity6 @entity583 @entity204 @entity734
OBJECTIVE: To investigate the efficacy and long-term clinical benefits of @entity734 for dialysis @entity1 . BACKGROUND: It is unclear whether percutaneous coronary intervention (PCI) with @entity734 ( @entity734 ) implantation is associated with lower rates of major adverse cardiovascular events (MACE) or mortality compared to bare-metal stents (BMS). METHODS: From a nationwide cohort selected from Taiwan's National Health Insurance Research Database, we enrolled 2,835 dialysis @entity1 who were hospitalized for PCI treatment with stent implantation from Dec 1, 2006. Follow-up was from the date of index hospitalization for PCI until the first MACE, date of @entity204 , or December 31, 2011, whichever came first. RESULTS: A total of 738 @entity1 (26.0%) had @entity734 implanted, and 2,097 (74%) had BMS implanted. The medium time to the first MACE was 0.53 years (interquartile range: 0.89 years; range: 0-4.62 years). At 1-year follow-up, @entity1 treated with BMS had significantly, non-fatal @entity583 ( @entity583 ), all-cause mortality, and composite MACE compared to those treated with @entity734 . The overall repeat revascularization with coronary artery bypass graft (CABG), non-fatal @entity583 , all-cause mortality, and composite MACE were significantly lower in @entity1 treated with @entity734 than those treated with BMS. Multivariate cox regression analysis showed that older age, history of @entity6 , history of @entity712 , history of @entity64 , and @entity734 vs. BMS were independent significant predictors of MACE. CONCLUSIONS: @entity734 implantation conferred survival benefits in dialysis @entity1 compared with BMS implantation.
